Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Epitalon (Epithalon) | KPV | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 5-10 mg daily via subcutaneous injection for 10-20 day cycles. | Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation. |
| Timing | Evening administration preferred (aligns with pineal/melatonin function). Some protocols split doses AM/PM. | Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous. |
| Cycle Duration | 10-20 day intensive cycles repeated every 4-6 months. Not used continuously. | 4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
Epitalon (Ala-Glu-Asp-Gly / AEDG) is a synthetic tetrapeptide based on the natural pineal gland peptide epithalamin. It activates telomerase by inducing expression of the catalytic subunit hTERT, resulting in telomere elongation averaging 33.3% in human somatic cells. Epitalon restores pineal melatonin synthesis and circadian gene expression in aged organisms, increases BDNF, and upregulates CREB1. It also modulates the neuroendocrine system through its effects on the hypothalamic-pituitary axis and antioxidant enzyme regulation.
Research indicates 5-10 mg daily via subcutaneous injection for 10-20 day cycles.
Evening administration preferred (aligns with pineal/melatonin function). Some protocols split doses AM/PM.
10-20 day intensive cycles repeated every 4-6 months. Not used continuously.
KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) that inhibits NF-kB signaling through a non-melanocortin receptor-mediated mechanism. It is transported intracellularly via the PepT1 transporter, where it stabilizes IkB-alpha and suppresses nuclear translocation of p65RelA by competing with importin-beta at the armadillo domain 7 and 8 binding site. It also reduces MAPK inflammatory signaling and IL-8 secretion in intestinal epithelial cells.
Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation.
Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous.
4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →